Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 April, 2018 18:43 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Bharti Infratel quarterly profit climbs 1.58% - 23-Apr-2018 18:10
Mahindra Powerol launches new range of high power diesel generators - 23-Apr-2018 13:36
Gujarat Ambuja Exports completes 1st phase of greenfield maize processing plant - 23-Apr-2018 12:58
Lupin receives USFDA for generic of Xenazine tablets - 23-Apr-2018 12:52
Indian Overseas Bank signs agreement with NeSL - 23-Apr-2018 10:21
HDFC Bank Q4 net grows 20% to Rs 47.99 bn - 23-Apr-2018 10:17
Indian Hume Pipe Co secures work order worth Rs 5.78 bn - 23-Apr-2018 10:00
Welspun Corp bags contract to supply water pipes in MENA region - 20-Apr-2018 10:17
TVS Motor Company launches TVS XL100 Heavy Duty 'i-Touch Start' - 20-Apr-2018 10:14
Yes Bank receives RBI approval to open overseas offices - 20-Apr-2018 10:07
Glenmark Pharma gets final nod for Clobetasol Propionate solution - 20-Apr-2018 10:03
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer